VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for The Female Health Company (VERU Inc.) for the three-month period ended December 31, 2008. The Company manufactures, markets, and distributes the FC1 and FC2 female condoms, the only FDA-approved products under a woman's control for preventing unintended pregnancy and sexually transmitted diseases (including HIV/AIDS). The Company operates manufacturing facilities in London, England (FC1) and Selangor, Malaysia (FC2), with sales in 116 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 7% ($389,913) primarily due to a higher sales mix of the lower-priced FC2 product compared to FC1.
• Profitability Increase: Despite lower revenue, Net Income increased 91% ($778,780). This was driven by a significant non-operating foreign currency transaction gain of $1,194,107 (compared to $115,358 in the prior year) resulting from the strengthening of the U.S. dollar against the British pound and the Malaysian ringgit.
• Operating Expenses: Operating income decreased 40% due to a 25% increase in Selling, General, and Administrative (SG&A) expenses. SG&A rose due to higher compensation costs, Sarbanes-Oxley consulting fees, and one-time costs related to the FC2 FDA approval process.
• Cash Flow: Operating cash flow more than doubled to $3.4 million, aided by a significant reduction in accounts receivable ($3.4 million decrease) due to timing of shipments and collections.
• Stock Repurchases: The Company repurchased 458,400 shares of common stock during the quarter for approximately $1.4 million, leaving 700,600 shares remaining under the current repurchase program.

Guidance, Outlook, and Risks

• FC2 FDA Approval: The FDA's OB/GYN Device Advisory Committee unanimously recommended approval of the FC2 female condom in December 2008 with a single condition regarding labeling. The Company is finalizing package labeling and directions. Approval is expected to enable procurement by USAID for global prevention programs.
• Market Strategy: The Company continues to focus on public sector distribution (UNAIDS, USAID) and expanding commercial partnerships. FC2 is positioned as a more cost-effective alternative to FC1.
• Liquidity: Management believes current cash ($3.2 million) is adequate for near-term operations. The Company has a $1.5 million revolving credit facility with Heartland Bank, with no amounts outstanding as of December 31, 2008.
• Risks:
  • Single Product Reliance: The Company derives virtually all revenue from female condoms.
  • Foreign Currency: Manufacturing costs are in GBP and MYR, while sales are often in USD. Fluctuations significantly impact reported earnings (as seen in the $1.2M gain this quarter).
  • Regulatory: Continued compliance with FDA regulations is critical; failure could result in withdrawal of approval.
  • Capital Needs: The Company may need to raise additional capital to fund working capital and promotional expenditures.

Investor Verification Checklist

• FC2 FDA Status: Verify the final FDA approval status of the FC2 product and the specific labeling conditions required.
• Currency Sensitivity: Assess the sustainability of earnings given the heavy reliance on foreign currency translation gains/losses rather than core operating margin expansion.
• Accounts Receivable: Confirm the trend in Days Sales Outstanding (DSO) to ensure the Q1 2009 reduction was due to timing rather than a permanent shift in collection efficiency.
• Stock Repurchase Program: Monitor the remaining 700,600 shares available for repurchase and the Company's cash burn rate relative to its $3.2 million cash balance.
• Public Sector Contracts: Review upcoming renewals of agreements with UNAIDS and USAID, which are critical to revenue stability.